Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Altimmune Inc (ALT) USD0.0001

Sell:$14.65 Buy:$14.95 Change: $0.38 (2.50%)
Market closed |  Prices as at close on 28 September 2021 | Switch to live prices |
Sell:$14.65
Buy:$14.95
Change: $0.38 (2.50%)
Market closed |  Prices as at close on 28 September 2021 | Switch to live prices |
Sell:$14.65
Buy:$14.95
Change: $0.38 (2.50%)
Market closed |  Prices as at close on 28 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Altimmune Inc is a clinical-stage immunotherapeutics company. The Company is focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company’s product candidates include ALT-801, HepTcell, ALT-702, NasoVAX and NasoShield. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of cancer indications. NasoVAX, its influenza vaccine candidate that stimulate multiple arms of the immune system and offers the potential to stop the infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is an intranasal anthrax vaccine candidate that is designed to provide more rapid and stable protection than the only approved anthrax vaccine.

Contact details

Address:
910 Clopper Rd Ste 201S
GAITHERSBURG
20878-1361
United States
Telephone:
+1 (240) 6541450
Website:
https://altimmune.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ALT
ISIN:
US02155H2004
Market cap:
$594.40 million
Shares in issue:
39.71 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Vipin Garg
    President, Chief Executive Officer, Director
  • William Brown
    Chief Financial Officer, Principal Accounting Officer
  • M. Scot Roberts
    Chief Scientific Officer
  • M. Scott Harris
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.